Immix Biopharma Accelerates U.S. NEXICART-2 Clinical Trial In Relapsed/Refractory AL Amyloidosis; Says It Is On Track For First BLA Approved Cell Therapy In Unaddressed Orphan Indication

– National Footprint of NEXICART-2 Trial Sites Expanded –

–  On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –

–  NEXICART-2 interim results were presented at ASCO 2025 –

LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18 clinical trial sites in its national footprint.